0 182

Cited 0 times in

Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.date.accessioned2021-12-28T17:06:19Z-
dc.date.available2021-12-28T17:06:19Z-
dc.date.issued2021-08-
dc.identifier.issn1936-0533-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186938-
dc.description.abstractBackground: Controlled attenuation parameter (CAP) can evaluate hepatic steatosis in patients with chronic hepatitis B (CHB). However, prognostic implications of CAP value remain unclear. We evaluated the association between CAP and the risk of hepatocellular carcinoma (HCC) in patients with CHB under antiviral therapy and maintained virologic response. Methods: A total of 1823 CHB patients who were taking nucleos(t)ide analogue and showing suppressed hepatitis B virus replication were analyzed. The primary outcome was incident HCC during follow-up. Patients were grouped into those with and without advanced chronic liver disease (ACLD) (liver stiffness measurement cutoff: 10 kPa), and those with and without hepatic steatosis (CAP cutoff: 222 dB/m). Results: During 6.4 years of follow-up, 127 patients (7.0%) newly developed HCC. Among patients with ACLD (n = 382), the cumulative HCC incidence rate was lower for those with CAP ≥ 222 (11.0% at 5 years) than those with CAP < 222 (24.0% at 5 years, p = 0.002), and was an independent factor associated with HCC. When CAP value was further stratified, the cumulative HCC incidence rate decreased in dose-dependent manner according to an increase in CAP value (24.0%, 13.9%, 12.8% and 6.0% at 5 years for those with CAP < 222, 222-246, 247-273 and ≥ 274, respectively). Among patients without ACLD (n = 1441), there was no significance difference in HCC risk according to CAP value (HCC incidence rate: 3.3% and 4.0% at 5 years for those with CAP < 222 and CAP ≥ 222, p = 0.20). Conclusions: Among CHB patients under antiviral therapy showing suppressed HBV replication, low CAP value predicted higher risk for HCC among ACLD patients, indicating that CAP value has a prognostic implication in this population.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfHEPATOLOGY INTERNATIONAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents / therapeutic use-
dc.subject.MESHCarcinoma, Hepatocellular* / drug therapy-
dc.subject.MESHCarcinoma, Hepatocellular* / epidemiology-
dc.subject.MESHCarcinoma, Hepatocellular* / etiology-
dc.subject.MESHElasticity Imaging Techniques-
dc.subject.MESHHepatitis B virus-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHLiver Cirrhosis / drug therapy-
dc.subject.MESHLiver Neoplasms* / drug therapy-
dc.subject.MESHLiver Neoplasms* / epidemiology-
dc.subject.MESHLiver Neoplasms* / etiology-
dc.subject.MESHRisk Factors-
dc.titleControlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJoo Hyun Oh-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorDong Hyun Sinn-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorWonseok Kang-
dc.contributor.googleauthorGeum-Youn Gwak-
dc.contributor.googleauthorMoon Seok Choi-
dc.contributor.googleauthorJoon Hyeok Lee-
dc.contributor.googleauthorKwang Cheol Koh-
dc.contributor.googleauthorSeung Woon Paik-
dc.contributor.googleauthorYong-Han Paik-
dc.identifier.doi10.1007/s12072-021-10205-7-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ00986-
dc.identifier.eissn1936-0541-
dc.identifier.pmid34260013-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12072-021-10205-7-
dc.subject.keywordChronic hepatitis B-
dc.subject.keywordControlled attenuation parameter-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordTransient elastography-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume15-
dc.citation.number4-
dc.citation.startPage892-
dc.citation.endPage900-
dc.identifier.bibliographicCitationHEPATOLOGY INTERNATIONAL, Vol.15(4) : 892-900, 2021-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.